Healthcare Giants Demand Hard Evidence as AI Vendors Promise the Moon

The honeymoon phase for healthcare AI vendors appears to be over. As artificial intelligence companies tout ever-bolder promises of cost savings and efficiency gains, major health systems are demanding something fundamental: concrete proof that these technologies actually deliver.

Organizations including Mass General Brigham, Valleywise Health, and Evergreen Health are leading a procurement revolution, implementing rigorous vetting processes that prioritize evidence over marketing hype. The shift signals a critical maturation point in healthcare's relationship with AI technology—one where theoretical capabilities must give way to demonstrated results.

From Promises to Performance-Based Contracts

Healthcare IT leaders are fundamentally restructuring how they engage with AI vendors. Rather than accepting vendor projections at face value, health systems now demand independent validation of return-on-investment claims before signing contracts. More significantly, they're tying vendor payments directly to performance outcomes.

This represents a dramatic departure from traditional procurement models. Extended pilot periods with clearly defined success metrics have become standard practice, allowing organizations to evaluate AI tools in real-world conditions before committing substantial resources. Health systems are also requiring vendors to demonstrate measurable outcomes in similar healthcare settings—not just theoretical models or results from vastly different environments.

Evidence Requirements Raise the Bar

The new procurement standards demand comprehensive evidence packages that go far beyond sales presentations. Health systems now require peer-reviewed studies, real-world deployment data, and transparent methodology documentation as baseline requirements for consideration.

This evidence-based approach serves as a protective mechanism against costly failed implementations. By demanding proof upfront, healthcare organizations can more accurately budget for AI initiatives and allocate resources to technologies with demonstrated value rather than speculative potential. The strategy also helps identify vendors willing to stand behind their claims versus those relying on aspirational projections.

For patients, this heightened scrutiny should translate into deployment of clinically validated AI tools that genuinely improve care quality, safety, and efficiency—rather than unproven technologies that consume healthcare dollars without measurable benefit.

A New Competitive Landscape Emerges

This procurement evolution is reshaping the healthcare AI marketplace. Vendors prepared to accept performance-based contracts and provide comprehensive evidence documentation gain competitive advantage, while companies relying solely on theoretical capabilities face significant barriers to adoption.

The shift may slow AI adoption in the near term, but it promises a more sustainable long-term trajectory. By filtering out unproven technologies and rewarding vendors who deliver measurable results, health systems are creating market incentives that drive genuine innovation rather than marketing innovation.

As healthcare organizations continue refining these evidence-based procurement strategies, the AI vendors that survive and thrive will be those that can prove their worth—not just promise it.

Sources

1. As AI vendor ROI claims grow bolder, health systems require more proof — Becker's Hospital Review